Kisspeptin vs Letrozole
Emerging vs FDA Approved
synergistic Mechanism-based · 49% Letrozole helps manage estrogen conversion from Kisspeptin. This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen.
Molecular Data
Kisspeptin Letrozole
Weight 1,213.42 Da (KP-10) / 6,087 Da (KP-54) 285.30 Da
Half-life ~4 minutes (KP-10), ~28-32 minutes (KP-54) ~2 days (48 hours)
Chain 10-54 amino acids —
Type Neuropeptide family (RFamide) Nonsteroidal aromatase inhibitor (triazole derivative)
Key Benefits
Kisspeptin
01 Potent reproductive hormone stimulation (LH/FSH)
02 Restoration of natural testosterone production
03 Fertility enhancement
04 Sexual function support
05 Hypogonadism treatment potential
Letrozole
01 Most potent aromatase inhibitor available, achieving ~98% estradiol suppression at medical doses
02 Effective rescue compound for acute gynecomastia flare-ups unresponsive to other AIs
03 Capable of managing estrogen on very high aromatizing cycles where anastrozole is insufficient
04 Oral dosing with a 2-day half-life supports every-other-day scheduling
05 Well-characterized pharmacokinetics with extensive clinical data from breast cancer treatment
06 Reversible inhibition allows estrogen recovery after discontinuation
07 FDA-approved with decades of safety and efficacy data
Dosing Protocols
Kisspeptin
100-200 mcg per injection / Single dose for testing, or 2-3 times weekly (NEVER daily - causes desensitization)
Gonadotropin stimulation 100-200mcg Single dose or 2-3x weekly
Fertility support 0.4-1.0 nmol/kg (50-150mcg) As directed by physician
Sexual function (clinical) 1 nmol/kg/h 75-minute IV infusion
Letrozole
0.25-0.5mg EOD (on-cycle); 2.5mg/day (medical) / Every other day (cycle support); daily (breast cancer / fertility)
Side Effects
Kisspeptin
Minimal acute side effects reported
Potential mild cardiovascular effects
Letrozole
Severe joint pain, stiffness, and dryness (the hallmark side effect of aggressive estrogen suppression)
Fatigue and profound lethargy
Mood disturbance (depression, emotional flatness, irritability)
Decreased libido and sexual dysfunction
Hot flashes or flushing
Headache
Muscle aches and generalized pain
Contraindications
Not recommended during pregnancy or breastfeeding
Caution with cardiovascular disease history
Daily dosing causes receptor desensitization
Known hypersensitivity to letrozole or any excipients
Premenopausal women (unless under specialist care for fertility treatment)
Pregnancy or breastfeeding (teratogenic risk -- letrozole is Category X)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
History of estrogen-crash-related adverse events with prior AI use
Research Evidence
Kisspeptin Letrozole
Status Emerging FDA Approved
References 4 studies 5 studies
Latest 2025 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.